Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Babesia microti antigens are a diverse group of proteins expressed on the surface or secreted by the Babesia microti parasite, the primary causative agent of human babesiosis. These antigens, including BmGPI12, BmAMA1, and BmGP15, play critical roles in the parasite's life cycle, particularly in the attachment to and invasion of host erythrocytes and the evasion of the host immune system. They are the primary targets of the human humoral immune response, where the production of specific antibodies (IgG and IgM) is essential for controlling and clearing the infection. In clinical diagnostics, these antigens and the corresponding human antibodies serve as vital biomarkers for identifying active or past infections. From a therapeutic perspective, these antigens are being investigated as candidates for recombinant vaccines and as targets for passive immunization using monoclonal antibodies, which may offer a novel treatment pathway for persistent or relapsing babesiosis in immunocompromised individuals.
Inhibition of parasite invasion, neutralization of parasite surface proteins, and opsonization for phagocytosis.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Babesia microti antigens.